The London Research Institute research groups are based at Lincoln’s Inn Fields and Clare Hall. Our major research themes are: the biology of tumours and tissues, cellular regulatory mechanisms and genomic integrity and cell cycle.
Peter Parker : Protein Phosphorylation
Publications
2012
Milanovic M, Radtke S, Peel N, Howell M, Carrière V, Joffre C, Kermorgant S, Parker PJ. Anomalous inhibition of c-Met by the kinesin inhibitor aurintricarboxylic acid. Int J Cancer. 2012 130(5):1060-70
(Abstract)
2011
Cameron AJ, Linch MD, Saurin AT, Escribano C, Parker PJ. Dissecting the role of Sin1 in AGC kinase regulation by TORC2. Biochem J. 2011 Aug 1. [Epub ahead of print]
(Abstract)
Cameron AJ, Linch MD, Saurin AT, Escribano C, Parker PJ. mTORC2 targets AGC kinases through Sin1-dependent recruitment. Biochem J. 2011;15;439(2):287-97
(Abstract)
Carlin LM, Evans R, Milewicz H, Fernandes L, Matthews DR, Perani M, Levitt J, Keppler MD, Monypenny J, Coolen T, Barber PR, Vojnovic B, Suhling K, Fraternali F, Ameer-Beg S, Parker PJ, Thomas NS, Ng T. A Targeted siRNA Screen Identifies Regulators of Cdc42 Activity at the Natural Killer Cell Immunological Synapse. Sci Signal. 2011 Nov 29;4(201):ra81.
(Abstract)
Collazos A, Michael N, Whelan RD, Kelly G, Mellor H, Pang LC, Totty N, Parker PJ. Site recognition and substrate screens for PKN family proteins. Biochem J. 2011 Jul 12. [Epub ahead of print]
(Abstract)
Collazos A, Michael N, Whelan RD, Kelly G, Mellor H, Pang LC, Totty N, Parker PJ. Site recognition and substrate screens for PKN family proteins. Biochem J. 2011;438(3):535-43
(Abstract)
Kveiborg M, Instrell R, Rowlands C, Howell M, Parker PJ. PKCalpha and PKCdelta Regulate ADAM17-Mediated Ectodomain Shedding of Heparin Binding-EGF through Separate Pathways. PLoS One6. 2011;6(2):e17168
(Abstract)
Lachmann S, Jevons A, De Rycker M, Casamassima A, Radtke S, Collazos A, Parker PJ. Regulatory Domain Selectivity in the Cell-Type Specific PKN-Dependence of Cell Migration. PLoS One. 2011;6(7):e21732
(Abstract)
Salehi-Reyhani A, Kaplinsky J, Burgin E, Novakova M, deMello AJ, Templer RH, Parker P, Neil MA, Ces O, French P, Willison KR, Klug D. A first step towards practical single cell proteomics: a microfluidic antibody capture chip with TIRF detection. Lab Chip. 2011;11:1256
(Abstract)
Tynan CJ, Roberts SK, Rolfe DJ, Clarke DT, Loeffler HH, Kästner J, Winn MD, Parker PJ, Martin-Fernandez ML. Human Epidermal Growth Factor Receptor (EGFR) Aligned on the Plasma Membrane Adopts Key Features of Drosophila EGFR Asymmetry. Mol Cell Biol. 2011;31(11):2241-52
(Abstract)
Verma SK, Ganesan TS, Kishore U, Parker PJ. The tumor suppressor RASSF1A is a novel effector of small G protein Rap1A. Protein Cell. 2011;2(3):237-49
(Abstract)
2010
Boeckeler K, Rosse C, Howell M, Parker PJ. Manipulating signal delivery - plasma-membrane ERK activation in aPKC-dependent migration. J Cell Sci. 2010;123(Pt 16):2725-32
(Abstract)
Cameron, A. J. and Parker, P. J. (2010) Protein kinase C - A family of protein kinases, allosteric effectors or both? Adv Enzyme Regul
(Abstract)
Chen WQ, Graf C, Zimmel D, Rovina P, Krapfenbauer K, Jaritz M, Parker PJ, Lubec G, Bornancin, F. Ceramide kinase profiling by mass spectrometry reveals a conserved phosphorylation pattern downstream of the catalytic site. J Proteome Res. 2010;9:420-429
(Abstract)
Chen, W. Q., Graf, C., Zimmel, D., Rovina, P., Krapfenbauer, K., Jaritz, M., Parker, P. J., Lubec, G. and Bornancin, F. (2010) Ceramide kinase profiling by mass spectrometry reveals a conserved phosphorylation pattern downstream of the catalytic site. J Proteome Res. 9, 420
(Abstract)
Durgan J, Parker PJ. Regulation of the tumour suppressor Fbw7alpha by PKC dependent phosphorylation and cancer associated mutation. Biochem J. 2010;432(1):77-87
(Abstract)
Flinn RJ, Yan Y, Goswami S, Parker PJ, Backer JM. The late endosome is essential for mTORC1 signaling. Mol Biol Cell. 2010;21:833
(Abstract)
Gijsen M, King P, Perera T, Parker P, Larijani B, Harris A, Kong A. Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer. Breast Cancer Res. 2010;12(1):O2.
(Abstract)
Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol. 2010;8:e1000563
(Abstract)
Rosse C, Linch M, Kermorgant S, Cameron AJ, Boeckeler K, Parker PJ. PKC and the control of localized signal dynamics. Nat Rev Mol Cell Biol. 2010;11(2):103-12
(Abstract)
Pages
Team |
Projects |
Goals |
Resources |
